XNAS
STTK
Market cap511mUSD
Oct 08, Last price
5.66USD
1D
0.09%
1Q
-14.76%
IPO
-70.21%
Name
Shattuck Labs Inc
Chart & performance
P/E
—
P/S
511.51
EPS
—
Div yield, %
—
Shrs. gr., 5y
10.75%
Rev. gr., 5y
-36.82%
Revenues
1m
-82.52%
Net income
-49m
L-35.28%
CFO
-40m
L-34.10%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Shattuck Labs, Inc. operates as a biotechnology firm based in the United States, currently at the clinical development stage. Its core mission is to create innovative therapeutics designed to combat both cancer and autoimmune diseases. The company's leading experimental compound, SL-172154, is presently undergoing Phase 1 clinical assessment for the treatment of ovarian, fallopian tube, and peritoneal cancers. Furthermore, Shattuck Labs is advancing another product candidate, SL-279252, which is also in Phase 1 trials for patients afflicted with advanced solid tumors and lymphoma. Established in 2016, the company maintains its corporate headquarters in Austin, Texas.
Key people
Independent Chairman of the Board · since 2021
Andrew Neill
Chief Financial Officer · since 2021
Stephen Stout
General Counsel, Corporate Secretary and Chief Ethics and Compliance Officer · since 2023
Casi Deyoung
Chief Business Officer · since 2019
Arundathy Pandite
Chief Medical Officer · since 2017
Abhinav Shukla
Chief Technical Officer · since 2021
Director · since 2025
Taylor Schreiber
Chief Executive Officer, Co-Founder, Director · since 2020
Daniel Baker
Independent Director · since 2025
Independent Director · since 2020
Independent Director · since 2016
Kate Sasser
Independent Director · since 2024
Clay Siegall
Independent Director · since 2024
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | |
| Income | ||||||||
Revenues | ||||||||
Cost of revenue | ||||||||
Unusual Expense (Income) | ||||||||
NOPBT | ||||||||
NOPBT Margin | ||||||||
Operating Taxes | ||||||||
Tax Rate | ||||||||
NOPAT | ||||||||
Net income | ||||||||
Dividends | ||||||||
Dividend yield | ||||||||
Proceeds from repurchase of equity | ||||||||
BB yield | ||||||||
| Debt | ||||||||
Debt current | ||||||||
Long-term debt | ||||||||
Deferred revenue | ||||||||
Other long-term liabilities | ||||||||
Net debt | ||||||||
| Cash flow | ||||||||
Cash from operating activities | ||||||||
CAPEX | ||||||||
Cash from investing activities | ||||||||
Cash from financing activities | ||||||||
FCF | ||||||||
| Balance | ||||||||
Cash | ||||||||
Long term investments | ||||||||
Excess cash | ||||||||
Stockholders' equity | ||||||||
Invested Capital | ||||||||
ROIC | ||||||||
ROCE | ||||||||
| EV | ||||||||
Common stock shares outstanding | ||||||||
Price | ||||||||
Market cap | ||||||||
EV | ||||||||
EBITDA | ||||||||
EV/EBITDA | ||||||||
Interest | ||||||||
Interest/NOPBT | ||||||||